BRIDGEBIO PHARMA INC (BBIO) Stock Price, Quote, News and Overview
NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD
BBIO Quote, Performance and Key Statistics
33.26
-2.42 (-6.78%)
The current stock price of BBIO is 33.26 USD. In the past month the price decreased by -4.56%. In the past year, price increased by 10.54%.
BBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.57B | ||
| AMGN | AMGEN INC | 13.03 | 145.41B | ||
| GILD | GILEAD SCIENCES INC | 13.1 | 126.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.96 | 61.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.71B | ||
| ARGX | ARGENX SE - ADR | 92.41 | 33.12B | ||
| ONC | BEIGENE LTD-ADR | 5.58 | 24.22B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.72B | ||
| NTRA | NATERA INC | N/A | 20.70B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.28B | ||
| BIIB | BIOGEN INC | 7.79 | 18.05B |
Related stock screener links
About BBIO
Company Profile
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 725 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Company Info
BRIDGEBIO PHARMA INC
3160 Porter Dr., Suite 250
Palo Alto CALIFORNIA 94301 US
CEO: Neil Kumar
Employees: 728
Phone: 16503919740
BRIDGEBIO PHARMA INC / BBIO FAQ
What is the stock price of BRIDGEBIO PHARMA INC today?
The current stock price of BBIO is 33.26 USD. The price decreased by -6.78% in the last trading session.
What is the ticker symbol for BRIDGEBIO PHARMA INC stock?
The exchange symbol of BRIDGEBIO PHARMA INC is BBIO and it is listed on the Nasdaq exchange.
On which exchange is BBIO stock listed?
BBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BRIDGEBIO PHARMA INC stock?
24 analysts have analysed BBIO and the average price target is 60.44 USD. This implies a price increase of 81.7% is expected in the next year compared to the current price of 33.26. Check the BRIDGEBIO PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BRIDGEBIO PHARMA INC worth?
BRIDGEBIO PHARMA INC (BBIO) has a market capitalization of 6.32B USD. This makes BBIO a Mid Cap stock.
How many employees does BRIDGEBIO PHARMA INC have?
BRIDGEBIO PHARMA INC (BBIO) currently has 728 employees.
What are the support and resistance levels for BRIDGEBIO PHARMA INC (BBIO) stock?
BRIDGEBIO PHARMA INC (BBIO) has a support level at 32.11. Check the full technical report for a detailed analysis of BBIO support and resistance levels.
Is BRIDGEBIO PHARMA INC (BBIO) expected to grow?
The Revenue of BRIDGEBIO PHARMA INC (BBIO) is expected to grow by 85.18% in the next year. Check the estimates tab for more information on the BBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BRIDGEBIO PHARMA INC (BBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BBIO, evaluating the profitability, health, valuation and growth aspects
- BRIDGEBIO PHARMA INC (BBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRIDGEBIO PHARMA INC (BBIO) Sales and EPS estimates to see what analysts future expectations are.
- BRIDGEBIO PHARMA INC (BBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRIDGEBIO PHARMA INC (BBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRIDGEBIO PHARMA INC (BBIO) Stock Chart to make your own analysis
- BRIDGEBIO PHARMA INC (BBIO) Latest news and press-releases to stay up to date.
Does BRIDGEBIO PHARMA INC (BBIO) stock pay dividends?
BBIO does not pay a dividend.
When does BRIDGEBIO PHARMA INC (BBIO) report earnings?
BRIDGEBIO PHARMA INC (BBIO) will report earnings on 2025-07-30, before the market open.
What is the Price/Earnings (PE) ratio of BRIDGEBIO PHARMA INC (BBIO)?
BRIDGEBIO PHARMA INC (BBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.77).
What is the Short Interest ratio of BRIDGEBIO PHARMA INC (BBIO) stock?
The outstanding short interest for BRIDGEBIO PHARMA INC (BBIO) is 14.2% of its float. Check the ownership tab for more information on the BBIO short interest.
BBIO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BBIO. When comparing the yearly performance of all stocks, BBIO turns out to be only a medium performer in the overall market: it outperformed 67.32% of all stocks.
BBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BBIO. BBIO has a bad profitability rating. Also its financial health evaluation is rather negative.
BBIO Financial Highlights
Over the last trailing twelve months BBIO reported a non-GAAP Earnings per Share(EPS) of -3.77. The EPS decreased by -17.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.76% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to BBIO. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of -23.91% and a revenue growth 85.18% for BBIO